title: [Effectiveness of topical bevacizumab in bilateral primary lipid keratopathy].
abstract: METHODS
  A 75-year-old man with bilateral idiopathic lipid keratopathy underwent a penetrating keratoplasty in the left eye. One month later, there was deep corneal neovascularisation extending across the bed and the graft-host interface, with a whitish opacity surrounding the vessels. Topical bevacizumab (25mg/mL) was administered 4 times daily for 2 months with partial regression of corneal neovascularization.
  
  
  CONCLUSIONS
  Topical bevacizumab may be useful in preventing a recurrence of lipid deposition after penetrating keratoplasty in patients with bilateral primary lipid keratopathy, although its long-term efficacy needs to be assessed.
authors: Servicio de Oftalmología, Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, Madrid, España. cinta.perezrico@gmail.com
authors: M
authors: M
authors: Castro-Rebollo
authors: M A
authors: MA
authors: Montes-Mollón
authors: C
authors: C
authors: Pérez-Rico
authors: M A
authors: MA
authors: Teus
mesh_terms: D060433:Administration, Ophthalmic; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D003318:Corneal Opacity / Q000150:complications / Q000601:surgery*; D006801:Humans; D015948:Keratoplasty, Penetrating; D008055:Lipids; D008297:Male; D033401:Microscopy, Acoustic; D055502:Secondary Prevention
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D008055:Lipids; D000068258:Bevacizumab